ArticleScientific reports2016
Serum Autotaxin is a Marker of the Severity of Liver Injury and Overall Survival in Patients with Cholestatic Liver Diseases.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Quality of life in primary sclerosing cholangitis: a systematic review.Health and quality of life outcomes · 2021Pooled it
- Pruritus is common in primary sclerosing cholangitis, persists over time, and its intensity is associated with disease severity: a multicentre, prospective observational study.Hepatology (Baltimore, Md.) · 2026Observational
- Scratching the Surface: Lipidomic Profiling of the Stratum Corneum in the Search for Pruritogens in Cholestatic Liver Diseases.Journal of personalized medicine · 2026Review
- Article
- Role of FXR Agonist in Cholestasis Following Live Donor Liver Transplantation: A Randomized Open-Label Trial.Cureus · 2025Article
- Longitudinal Comparison of Currently Used Risk Scores for Prognostication of Primary Sclerosing Cholangitis (PSC) in a Hungarian Bicenter PSC Cohort.Diagnostics (Basel, Switzerland) · 2025Article
- Article
- Integrative bioinformatics analysis and experimental validation of key biomarkers for risk stratification in primary biliary cholangitis.Arthritis research & therapy · 2023Article
- Shared biological mechanisms of depression and obesity: focus on adipokines and lipokines.Aging · 2023Review
- Systematic review: efficacy of therapies for cholestatic pruritus.Therapeutic advances in gastroenterology · 2023Review
- A common variant in the hepatobiliary phospholipid transporter ABCB4 modulates liver injury in PBC but not in PSC: prospective analysis in 867 patients.Orphanet journal of rare diseases · 2022Article
- Autotaxin Activity in Chronic Subdural Hematoma: A Prospective Clinical Study.Diagnostics (Basel, Switzerland) · 2022Article
- Urinary BA Indices as Prognostic Biomarkers for Complications Associated with Liver Diseases.International journal of hepatology · 2022Article
- Autotaxin, PPARs, and FGF21: An Eye Opener for Progressive Liver Disease?Cellular and molecular gastroenterology and hepatology · 2022Article
- Hepatocyte-Secreted Autotaxin Exacerbates Nonalcoholic Fatty Liver Disease Through Autocrine Inhibition of the PPARα/FGF21 Axis.Cellular and molecular gastroenterology and hepatology · 2022Article
- Systematic Review of Prognostic Models Compared to the Mayo Risk Score for Primary Sclerosing Cholangitis.Journal of clinical medicine · 2021Review
- Cholestasis-Associated Pruritus and Its Pruritogens.Frontiers in medicine · 2021Review
- Autotaxin: An Early Warning Biomarker for Acute-on-chronic Liver Failure.Journal of clinical and translational hepatology · 2020Article
- Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities.Journal of gastroenterology · 2020Review
- Identifying Novel ATX Inhibitors via Combinatory Virtual Screening Using Crystallography-Derived Pharmacophore Modelling, Docking Study, and QSAR Analysis.Molecules (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autotaxin (ATX) is involved in the synthesis of lysophosphatidic acid. Both have recently been linked to cholestatic pruritus and liver injury. We aimed to investigate whether ATX is an indicator of cholestatic liver injury, health-related quality of life (HRQoL) and prognosis based on a group of 233 patients, 118 with primary biliary cholangitis (PBC) and 115 with primary sclerosing cholangitis (PSC). Patients were followed for 1-60 months, cumulative survival rates were calculated. ATX activity was significantly higher in both groups than in the 103 controls, particularly in patients with cirrhosis and in patients with longer disease duration. Ursodeoxycholic acid (UDCA) non-responders with PBC exhibited increased ATX activity. ATX activity was correlated with liver biochemistry, MELD, Mayo Risk scores and was associated with worse disease-specific HRQoL aspects. In both groups, Cox model analysis indicated that ATX was a negative predictor of survival. Increased ATX levels were associated with a 4-fold higher risk of death/liver transplantation in patients with PBC and a 2.6-fold higher risk in patients with PSC. We conclude that in patients with cholestatic conditions, ATX is not only associated with pruritus but also indicates impairment of other HRQoL aspects, liver dysfunction, and can serve as a predictor of survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.